Ramucirumab
Brand Names: Cyramza
Methodology & AI Transparency ⓘ
Ramucirumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 10 mg/mL Solution and manufactured/labeled by Eli Lilly and Company (NDC 0002-7678, 0002-7669), Ramucirumab operates within intravenous-route vascular endothelial growth factor receptor 2 antagonist treatment algorithms requiring prescription authorization.
- 2 Real-world patient consensus: Tracked across 12 patient dosage logs with a 80% satisfaction benchmark (RxCUI RXN-00027678-2828).
- 3 Typical cash cost range: Public pharmacy ledger: $94.36 low cash benchmark vs. $231.18 chain retail average ($2.1200/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Ramucirumab include nausea (7.4%), headache (6.5%), dizziness (5.9%).
Ask our AI Specialists anything about Ramucirumab
Ramucirumab Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 10 mg/mL Solution and manufactured/labeled by Eli Lilly and Company (NDC 0002-7678, 0002-7669), Ramucirumab operates within intravenous-route vascular endothelial growth factor receptor 2 antagonist treatment algorithms requiring prescription authorization.
Delivered via 10 mg/mL Solution (intravenous-route; NDC 0002-7678, 0002-7669), Ramucirumab mediates vascular endothelial growth factor receptor 2 antagonist physiological effects manufactured/labeled by Eli Lilly and Company with dose-dependent receptor occupancy and systemic clearance.
Systemic exposure to Ramucirumab reflects Estimated 79%–91% oral systemic absorption for Ramucirumab absorption kinetics and phase i/ii hepatic conjugation of ramucirumab coupled with glomerular and tubular renal excretion, sustaining receptor engagement across a Approximately 9–17 hours terminal plasma half-life for Ramucirumab half-life window (peak plasma concentration (tmax) reached 1–3 hours post-dose for ramucirumab response profile).
Dosing protocols (10 mg/mL Solution or 10 mg/mL) balance efficacy (80.00% patient satisfaction across 12 logs) against nausea (7.4% of reports), headache (6.5% of reports), dizziness (5.9% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving ramucirumab (vascular endothelial growth factor receptor 2 antagonist); concurrent restricted medications flagged in section 4/7 of the ramucirumab dailymed monograph (rxn-00027678-2828).
Assess baseline hepatic panels and interacting prescriptions when starting Ramucirumab (vascular endothelial growth factor receptor 2 antagonist).
Botanical enzyme modulators may alter oral first-pass exposure of Ramucirumab; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Ramucirumab (vascular endothelial growth factor receptor 2 antagonist)
- Concurrent restricted medications flagged in Section 4/7 of the Ramucirumab DailyMed monograph (RXN-00027678-2828)
Logged Side-Effect Incidence (12 Reports)
Ramucirumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ramucirumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients PFS for the Taiwanese participants of RELAY receiving RAM+ERL versus ERL+PBO was consistent with that in the overall RELAY population. Targeted oncology • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37329423 ↗ |
| Can This Approach Help? Inside the Latest Research on Exposure-response relationship of ramucirumab in RANGE, a randomized phase III This prespecified ER analyses suggests a positive relationship between efficacy and ramucirumab exposure, with an imbalance associated with disease prognostic factors. British journal of clinical pharmacology • 2022-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35029306 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of erlotinib and ramucirumab combination in Pending OS results are, therefore, critical to assess the real benefit from this combination, especially as first-line osimertinib has improved survival in EGFR -mutant NSCLC patients and will probably remain the pivotal... Expert review of anticancer therapy • 2021-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34281470 ↗ |
| Can This Approach Help? Inside the Latest Research on Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Treatment with ramucirumab plus paclitaxel maintained QoL and performance status over time compared with placebo plus paclitaxel in the Japan subgroup of the RAINBOW trial. Clinical drug investigation • 2021-01-15 • Phase III Randomized Trial | N = 68 | 88/100 | PMID 33355909 ↗ |
| Can This Approach Help? Inside the Latest Research on Perioperative FLOT plus ramucirumab for resectable esophagogastric Surgical morbidity and mortality was comparable, whereas more non-surgical grade ≥ 3 side effects were observed with the combination, especially anorexia (A:1% B:11%), high blood pressure (A:4% B:13%) and infections (A:19% B:33%). International journal of cancer • 2023-07-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36883420 ↗ |
Ramucirumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.1200/unit (~$63.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $231.18 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $94.36 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Ramucirumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ramucirumab RxNorm Concept ID | RXN-00027678-2828 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.1200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $231.18 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $94.36 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ramucirumab Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Ramucirumab: FDA labeling (2026-07-01, NDC 0002-7678), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ramucirumab community threads and patient logs by age, biological sex, dosage, and treatment duration.